echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Biogen's next-generation fumaric acid product, Vumerity, has been approved by the UK MHRA

    Biogen's next-generation fumaric acid product, Vumerity, has been approved by the UK MHRA

    • Last Update: 2022-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    Biogen Vumerity (diroximel fumarate), a next-generation oral fumarate therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS), has been approved by the Medicines and Healthcare Products Administration (MHRA) in the United Kingdom


    Vumerity is an upgraded version of Bojian's listed fumaric acid product Tecfidera (Chinese trade name: Tefida, generic name: dimethyl fumarate, dimethyl fumarate)


    The approval of Vumerity by the MHRA and EC is based on data from a pharmacokinetic bridging study comparing Vumerity and Tecfidera, in part on Tecfidera's established favorable long-term efficacy and safety profile, and results from the EVOLVE-MS-2 study


    The EVOLVE-MS-2 study is a large-scale, randomized, double-blind, 5-week, multicenter Phase 3 study to evaluate the gastrointestinal (GI) tolerability of Vumerity and Tecfidera in patients with RRMS


    Vumerity was first approved by the US FDA in October 2019


    Maha Radhakrishnan, M.


    Reference source: MHRA authorises Vumerity for multiple sclerosis patients

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.